Company intelligence / Profile preview

Lyra Medical

Watertown, Massachusetts, United Stateslyramedical.com ↗

Ownership: Private
Employees: ~51
Development stage: Commercial

Overview

Lyra Therapeutics has reported positive results from the ENLIGHTEN 2 Phase 3 trial of LYR-210, achieving statistically significant results for primary and key secondary endpoints in the treatment of chronic rhinosinusitis. The company is also presenting long-term extension data from its ENLIGHTEN 1 Phase 3 study

Therapeutic areas: PulmonologyOther
Modalities: DevicePolymer-drug conjugate therapySmall molecule (mometasone furoate)
Industry: Biotech

Partnerships

No major pharmaceutical or biotech partnerships disclosed; holds royalty-free global rights to all product candidates across all indications

Beyond the preview

Go deeper on Lyra Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lyra Medical.

Explore the full profile